Daiichi Sankyo in deal with Daewoong for Lixiana in South Korea

28 December 2015

Japanese pharma major Daiichi Sankyo (TYO: 4568) says its wholly-owned South Korean subsidiary has entered into an agreement with local drugmaker Daewoong Pharmaceutical for the co-promotion of the oral, once-daily anti-coagulant Lixiana (edoxaban).

Daewoong is also the co-promotion partner in South Korea for the Daiichi Sankyo antihypertensives Olmetec (olmesartan medoxomil), Olmetec Plus, Sevikar (olmesartan medoxomil and amlodipine besilate)and Sevikar HCT. Through this new agreement, Daiichi Sankyo Korea aims to maximize Lixiana’s product value and further contribute to disease treatment and prevention in South Korea.

Lixiana was approved in South Korea in August 2015 and will be launched within this fiscal year, the companies stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK